Business Wire

New Olympus Ultra-Portable EPOCH® 6LT Flaw Detector Provides Comprehensive Flaw Detection Capabilities for Rope Access and High Portability Inspections

Jaa

Optimized for single-handed operation, the EPOCH 6LT flaw detector combines a leading-edge ergonomic design with powerful ultrasonic functionality in an instrument built specifically for rope access and high portability applications.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170627005058/en/

The design of the EPOCH 6LT flaw detector, from form factor to the user interface, is optimized for user comfort, making it easy to use with one hand, so rope access inspection technicians and users that require high portability can do their work comfortably and efficiently.

  • Fits securely in one hand with minimal wrist fatigue: weighs just 1.95 lbs (890 g) with a grip-oriented weight distribution
  • Attaches to a user’s leg or harness: rope access technicians can secure the instrument for hands-free operation
  • Users can navigate the menu using just their thumb: the rotary knob and simple button design make it easy to navigate through the UI, even while wearing gloves
  • Durable and reliable: engineered to IP65/67 for dust and water resistance and drop tested to protect against the hazards found in challenging inspection environments

The EPOCH 6LT flaw detector’s workflow is simple and straightforward so technicians can spend more time on their inspection and less time adjusting the instrument. Despite the instrument’s small size, it has the features and functions to meet the requirements of nearly any conventional ultrasonic inspection application, including all the core functionality of the popular EPOCH 650 flaw detector and EN12668-1:2010 compliance.

  • Intuitive software: a two-screen, icon-based interface makes navigation quick and easy
  • Efficient inspections: the hardware and software maximize one-handed operation, so users can use their other hand to maneuver the probe
  • Optional corrosion software: combine the ease of use of a thickness gage with the flexibility of a flaw detector; with center-pin transducer ID for faster set up
  • Optional Wi-Fi connectivity: take advantage of on-the-go data backups, setup downloads, and powerful cloud applications on the Olympus Scientific Cloud

For rope access technicians, the EPOCH 6LT flaw detector offers features to help keep them safe during challenging inspections. For added efficiency, users can control the inspection parameters with one hand without interrupting flaw scanning. With the rope access accessory kit, technicians can secure the instrument to their leg or harness, leaving both hands free to maintain balance or adjust the probe. Depending on how the instrument is attached, the display rotates so users can properly view the A-scan and readings.

About Olympus

Olympus Corporation operates in industrial, medical, and consumer markets, specializing in optics, electronics, and precision engineering. Olympus is a world-leading manufacturer of innovative test and measurement solutions that are used in industrial and research applications ranging from aerospace, power generation, petrochemical, civil infrastructure, and automotive to consumer products.

For more information about the EPOCH 6LT flaw detector and Olympus’ full line of nondestructive testing products contact a sales representative or visit www.olympus-ims.com.

EPOCH is a registered trademark of Olympus Corporation.

Contact information

Olympus Corporation
Calvin Jory, 781-419-3549
Calvin.Jory@olympus-ossa.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Mitsui Chemicals Tohcello, Inc. Establishes a New Company in Taiwan23.10.2017 05:00Tiedote

Mitsui Chemicals, Inc. (Head Office: Minato-ku, Tokyo; President & CEO: Tsutomu Tannowa) announced that its wholly owned subsidiary, Mitsui Chemicals Tohcello, Inc. (Head Office: Chiyoda-ku, Tokyo; President & CEO: Yoshihisa Fujimaki) has decided to establish a company in Taiwan that will manufacture and sell the ICROS™Tape, a tape for semiconductor manufacturing. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171022005001/en/ ICROS(TM)Tape (Photo: Business Wire) The ICROS™Tape is a protective tape used for semiconductor manufacturing. It holds the world’s largest market share as a protective tape for the back grinding process of silicon wafer. The semiconductor market is experiencing growing demand attributable in part to the growth of mobile terminals. Demand is expected to continue to grow a

Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201721.10.2017 00:00Tiedote

Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are

More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 18:08Tiedote

The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable

Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 15:15Tiedote

Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside

Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 15:03Tiedote

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme